Academic History

Thomas Powles, MBBS, MRCP, MD, is Chair and Professor of Genitourinary Oncology at the Barts Cancer Institute, London, UK. He completed his medical school training at St Bartholomew’s Medical School, London, UK, in 1996, consequently training in Medical Oncology at Imperial College, London, UK. Following on, he completed his post-graduate training in Oncology, receiving an MD from the University of London, London, UK in 2006.

Prof. Powles co-leads both European Guidelines for Genitourinary cancer and the Uromigos podcast, keeping 400,000 listeners up to date on the latest genitourinary cancer developments. He was also featured in Nature’s selection of 10 global scientists 2023 and TIME’s 100 Healthcare List 2024.

Speaking on treatment of genital and urinary cancers

Prof. Powles is mainly interested in genitourinary cancers, and currently leads numerous Phase I-III trials investigating novel targeted and immune therapies. His main focuses include prognostic and predictive biomarkers, and the development of novel therapy agents – including front-line therapy combinations in renal cell carcinoma (RCC) and immune checkpoint inhibition in bladder cancer. His work has led to multiple EMA and FDA approvals and a deeper insight into refractory cancer biology.